Cerity Partners
CRNX

Cerity Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Cerity Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$903K Buy
24,133
+3,557
+17% +$132K ﹤0.01% 2060
2026
Q1 		$747K Buy
20,576
+1,602
+8% +$71.6K ﹤0.01% 2035
2025
Q4 		$883K Buy
+18,974
New +$845K ﹤0.01% 1775

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's CRNX Position: Q2 2026 in Review

Cerity Partners increased its Crinetics Pharmaceuticals (CRNX) stake by 17% in Q2 2026, buying an estimated $132K and bringing the position to 24,133 shares worth $903K. The position accounts for ﹤0.01% of the portfolio, ranked #2060.

Cerity Partners first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Cerity Partners held 24,133 shares of Crinetics Pharmaceuticals worth $903K as of Q2 2026.
  • Cerity Partners bought 3,557 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $132K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2060 holding.
  • Cerity Partners first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.